MYGN
What one share of Myriad Genetics holds
In Vitro and In Vivo Diagnostic Substances
Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights.
Myriad Genetics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $8.61 |
|---|---|
| Profit | −$1.20 |
| Cash and investments | $1.21 |
| Debt | $1.26 |
| Book value | $3.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $11.21 | $0.25 | $0.09 | $1.45 | — | $11.23 |
| 2018 | $10.33 | $1.85 | $0.12 | $1.49 | — | $13.68 |
| 2019 | $11.20 | $0.06 | $0.11 | $0.99 | — | $14.81 |
| 2020 | $8.59 | −$2.69 | $0.14 | $0.68 | — | $12.29 |
| 2020 | $7.45 | −$2.99 | — | — | — | $11.68 |
| 2021 | $8.85 | −$0.35 | $0.23 | $0.01 | — | $12.10 |
| 2022 | $8.42 | −$1.39 | $0.56 | −$1.88 | — | $10.91 |
| 2023 | $9.10 | −$3.18 | — | −$1.34 | — | $8.71 |
| 2024 | $9.24 | −$1.41 | — | −$0.10 | — | $7.68 |
| 2025 | $8.90 | −$3.95 | — | $0.02 | — | $3.94 |